Nexus - 0704 - New Times Magazine-pages

Page Content (OCR)

LY BD © oF VEN? "SON OF STAR WARS" COMING TO UK/EUROPE CASE AGAINST DR HULDA CLARK DISMISSED Fo a series of secret meet- Ne ings over the past six weeks in London, Washington and Brussels—involving members of the Clinton Administration and the British Cabinet, senior staff officers from the Pentagon and the British Ministry of Defence, senior man- agement from the US National Security Agency and British GCHQ, and representatives from NATO (on a strictly "need-to- know" basis)—Washington has been given permission to proceed with the first British stage of the "Son of Star Wars" program. This involves changes in computer soft- ware at the US satellite base at Fylingdales in North Yorkshire (Intelligence, no. 112, p. 26). Eventually the US$50 billion national missile protective shield, designed to pro- vide early warning of a rogue nuclear mis- sile attack against the US, will involve a massive extension to Menwith Hill, near Harrogate, and an arsenal of 200 "intercep- tors" set up in Britain, Denmark and the USA (North Dakota and Alaska). Although the system is not due to be tested until mid-May, President Bill Clinton has been under increasing pressure from the Republican-dominated Congress to agree to develop the technology. harges laid against Hulda Regehr Clark, PhD, ND, have been dismissed. Dr Clark was arrested in September 1999 and charged with practising medicine without a licence—a felony that can be punished with up to eight years in prison (see Global News 7/01). Dr Clark was released on bail a few weeks later, but the uncertainty over the outcome of her trial was a heavy burden on the 71-year-old researcher from San Diego, CA. Her enemies wanted to see her locked up behind bars. To the established medical interests, Dr Clark's workable therapy against cancer is a huge threat. But now the charges have been dismissed. David Amrein, President of the Dr Clark Research Association, has expressed his thanks to everyone who contributed to the legal fund or helped in other ways. He says the real fight is far from being over— the fight for individual freedom of choice in medical matters. (Source: Dr Clark Research Association, 18 April 2000, e-mail info@drclark.net, website www.drclark.net) Pointing out that London could not be expected to "turn down a request from our closest ally to change its computer soft- ware", a UK Cabinet spokesperson claimed that Prime Minister Tony Blair had "acted as a bridge between Europe and the US" in persuading the Pentagon to "share information about the missile shield technology" with its NATO allies. Exactly what the Europeans are to do with the data, which is bound to be heavily edited, wasn't mentioned in the statement. (Source: Intelligence (France), #115, 10 April 2000, www.blythe.org/Intelligence) DRUG MAKERS DON'T FINISH STUDIES AFTER LICENSURE D™ makers have consistently failed to conduct studies of their products after they are put on the market—studies that were often required by the FDA as a con- dition for a drug's approval, according to the consumer watchdog Public Citizen. Data that the group obtained from the FDA through the Freedom of Information Act shows that from 1990 to 1994, 88 new drugs were approved, based in part on the manufacturers’ commitment to do such studies (known as postmarketing or phase- four studies). Just 13% of the manufactur- ers of these drugs had completed the stud- ies as of December 1999, the group found. "This means that for at least five and as long as 10 years after drug approval, all of the studies for 87% of these drugs had not been completed," says Larry Sasich, PharmD, MPH, a spokesperson for Public Citizen, the group founded by consumer advocate Ralph Nader. (Sources: http://my.webmd.com/content/ article/1728.56650, via Sheri Nakken, AVN@egroups.com, 18 April 2000) 6 = NEXUS JUNE — JULY 2000